Browse Newsroom

Hans Othar Blix Joins InsuLife Advisory Board

March 31, 2021

InsuLife is pleased to announce the appointment of Hans Othar Blix to our Advisory Board. Hans is an investor and has been working in the field of business development for more than 25 years. He has served as a consultant or board member in more than fifty companies across Europe and the US.

Hans has broad international business experience and has expertise in investor relations, IPOs, private placements, mergers & acquisitions, restructuring, distressed situations, finance, strategic planning and execution, investor negotiations, venture funds, and exits.

Hans holds a Master of Business and Marketing from the Oslo Business School in Norway as well as a degree in computer science from EDB Høyskolen in Oslo, Norway. He currently resides in Boca Raton, Florida.

Hans holds 31 833 shares in Insulife AS through his holding company Skadi AS.

View Entire InsuLife Advisory Board

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved